- Description
- 1 online resource (v, 136 pages) : illustrations
- Alternative Title
- Examining Food and Drug Administration's generic drug and biosimilar user fee programs
- Subject
- Genre/Form
- Rules.
- Legislative hearings.
- Note
- Bibliography (note)
- Includes bibliographical references.
- Source of Description (note)
- Description based on online resource, PDF version; title from title page (govinfo, viewed July 7, 2021).
- Call Number
- GPO Internet Y 4.C 73/8:115-10
- OCLC
- marcive1259368245
- Author
United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health, author.
- Title
Examining FDA's generic drug and biosimilar user fee programs : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Fifteenth Congress, first session, March 2, 2017.
- Publisher
Washington : U.S. Government Publishing Office, 2018.
- Type of Content
text
- Type of Medium
computer
- Type of Carrier
online resource
- Bibliography
Includes bibliographical references.
- Connect to:
- Other Form:
Microfiche version: United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health. Examining FDA's generic drug and biosimilar user fee programs (OCoLC)1294314497
Print version: United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health. Examining FDA's generic drug and biosimilar user fee programs (DLC) 2018439914 (OCoLC)1078699092
- Gpo Item No.
1019-C-01 (online)
- Sudoc No.
Y 4.C 73/8:115-10